Kenji Ishii Selected Research

Glioma (Gliomas)

3/2024	Impact of [11C]methionine PET with Bayesian penalized likelihood reconstruction on glioma grades based on new WHO 2021 classification.
5/2019	Usefulness of [11C] Methionine PET in the Differentiation of Tumefactive Multiple Sclerosis from High Grade Astrocytoma.
7/2009	PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma.
6/2009	Contributions of biological tumor parameters to the incorporation rate of L: -[methyl-(11)C] methionine into astrocytomas and oligodendrogliomas.
9/2005	Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kenji Ishii Research Topics

Disease

44	Alzheimer Disease (Alzheimer's Disease) 03/2024 - 11/2007
14	Dementia (Dementias) 01/2023 - 11/2007
14	Cognitive Dysfunction 01/2022 - 07/2010
12	Neoplasms (Cancer) 03/2024 - 01/2004
12	Gliosis 02/2024 - 12/2017
11	Parkinson Disease (Parkinson's Disease) 07/2022 - 12/2002
6	Atrophy 02/2024 - 03/2010
5	Glioma (Gliomas) 03/2024 - 09/2005
5	Amyloid Plaque 01/2022 - 08/2012
4	Hemianopsia (Bitemporal Hemianopsia) 04/2024 - 01/2003
4	Corticobasal Degeneration 10/2023 - 08/2013
3	Astrocytoma (Pilocytic Astrocytoma) 04/2024 - 06/2009
3	Multiple Sclerosis 01/2021 - 05/2019
3	Cerebral Infarction 01/2021 - 12/2017
3	Stroke (Strokes) 01/2020 - 03/2003
3	Benign essential blepharospasm 01/2019 - 07/2007
3	Tauopathies 01/2019 - 11/2007
3	Insulin Resistance 01/2017 - 08/2015
3	Parkinsonian Disorders (Parkinsonism) 05/2016 - 01/2013
3	Multiple System Atrophy 09/2015 - 01/2008
3	Inflammation (Inflammations) 02/2013 - 08/2003
2	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2024 - 04/2014
2	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 10/2023 - 01/2023
2	Nervous System Diseases (Neurological Disorders) 07/2022 - 01/2021
2	Brain Neoplasms (Brain Tumor) 03/2022 - 11/2014
2	Progressive Multifocal Leukoencephalopathy 01/2021 - 01/2017
2	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 01/2021 - 01/2021
2	Pain (Aches) 09/2020 - 04/2014
2	Infarction (Infarctions) 01/2020 - 01/2016
2	Glioblastoma (Glioblastoma Multiforme) 06/2019 - 05/2018
2	Diffuse Axonal Injury 01/2018 - 01/2013
2	Cerebellar Ataxia (Dysmetria) 04/2017 - 11/2016
2	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 11/2016 - 08/2015
2	Glaucoma 11/2015 - 05/2013
2	Disease Progression 09/2015 - 04/2014
2	Diabetes Mellitus 02/2015 - 04/2008
2	Blepharospasm 01/2011 - 07/2003
2	Mental Disorders (Mental Disorder) 10/2007 - 02/2005
1	B-Cell Lymphoma (Lymphoma, B Cell) 04/2023
1	Lymphoma (Lymphomas) 04/2023
1	Neuronal intranuclear inclusion disease 01/2023
1	Neurocognitive Disorders (Clerambault Syndrome) 01/2023
1	Frontotemporal Dementia (Semantic Dementia) 01/2023
1	Lymphomatoid Granulomatosis (Granulomatosis, Lymphomatoid) 12/2022
1	Moyamoya Disease (Moya-Moya Disease) 04/2022
1	Lung Neoplasms (Lung Cancer) 01/2022
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 12/2021
1	postintensive care syndrome 12/2021
1	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/2021
1	Hemorrhage 01/2021

Drug/Important Bio-Agent (IBA)

35	Amyloid (Amyloid Fibrils)IBA 08/2023 - 11/2007
22	Glucose (Dextrose)FDA LinkGeneric 04/2024 - 01/2003
15	THK5351IBA 02/2024 - 12/2017
12	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 04/2023 - 06/2005
10	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 02/2024 - 03/2010
9	Methionine (L-Methionine)FDA Link 03/2024 - 08/2003
9	Monoamine Oxidase (MAO)IBA 10/2023 - 12/2017
8	Biomarkers (Surrogate Marker)IBA 08/2023 - 11/2016
7	Amyloid beta-PeptidesIBA 02/2024 - 11/2007
6	LigandsIBA 03/2024 - 11/2004
5	metabotropic glutamate receptor type 1IBA 01/2021 - 08/2015
5	Dopamine (Intropin)FDA LinkGeneric 09/2015 - 01/2008
4	Adenosine A1 ReceptorIBA 01/2018 - 12/2008
4	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 05/2016 - 04/2014
3	Oxygen (Dioxygen)IBA 04/2022 - 05/2004
3	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 01/2022 - 12/2018
3	Apolipoproteins E (ApoE)IBA 01/2021 - 01/2018
3	ApolipoproteinsIBA 01/2021 - 01/2018
3	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 01/2021 - 11/2016
3	Insulin (Novolin)FDA Link 01/2019 - 08/2015
3	Levodopa (L Dopa)FDA LinkGeneric 12/2018 - 01/2014
2	tau Proteins (tau Protein)IBA 02/2024 - 06/2019
2	SteroidsIBA 12/2021 - 10/2002
2	GadoliniumIBA 07/2021 - 08/2011
2	istradefyllineIBA 01/2021 - 12/2018
2	Proteins (Proteins, Gene)FDA Link 06/2019 - 01/2017
2	4- (N- methylamino)- 4'- (2- (2- (2- fluoroethoxy)ethoxy)ethoxy)stilbeneIBA 06/2016 - 08/2015
2	3-Iodobenzylguanidine (Iobenguane)IBA 04/2014 - 01/2012
2	GABA-A Receptors (GABA(A) Receptor)IBA 12/2012 - 05/2003
2	Adenosine (Adenocard)FDA LinkGeneric 02/2011 - 12/2008
2	Amino Acids FDA Link 07/2009 - 04/2005
2	Deoxyglucose (2 Deoxy D glucose)IBA 04/2008 - 04/2007
2	RacloprideIBA 02/2005 - 12/2002
2	CholesterolIBA 07/2004 - 06/2003
2	OxysterolsIBA 06/2003 - 02/2002
2	ParaquatIBA 06/2003 - 02/2002
1	5'-methylthioadenosine phosphorylase (methylthioadenosine nucleosidase)IBA 04/2024
1	Histone Deacetylase 6IBA 03/2024
1	Threonine (L-Threonine)FDA Link 01/2023
1	Acetic Acid (Vinegar)FDA LinkGeneric 01/2023
1	Homovanillic AcidIBA 01/2023
1	5-hydroxyindoleIBA 01/2023
1	1-dodecylpyridoxal (PLD)IBA 04/2022
1	AcidsIBA 03/2022
1	ErbB Receptors (EGF Receptor)IBA 01/2022
1	Coffee FDA Link 01/2022
1	Caffeine (No Doz)FDA LinkGeneric 01/2022
1	Selegiline (E250)FDA LinkGeneric 01/2021

Therapy/Procedure

9	Therapeutics 01/2019 - 03/2003
3	Drug Therapy (Chemotherapy) 12/2011 - 09/2005